Urology · Glendale, CA
NPI
1710915038
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
116 S Louise St
Glendale, CA, 91205
Phone (818) 507-4340
Groups this clinician bills Medicare through
Medicare paid, 2024
$522K
3,848 services
Medicare patients, 2024
583
Average age 76
Drug cost, 2024
$525K
5,034 prescriptions
Company payments, 2025
$365
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shahin Derboghossians was code 81002 (clinical chemistry), 331 times for 291 patients. In total Shahin Derboghossians billed 3,848 services in 44 codes, and Medicare paid $522K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 81002 Clinical Chemistry | Office | 331 | 291 | $3.41 | $1,129 |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 329 | 322 | $88.57 | $29K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 316 | 43 | $141.17 | $45K |
| 51729 Other Organ Systems | Office | 282 | 282 | $310.59 | $88K |
| 36415 Venipuncture Blood Collection | Office | 278 | 225 | $8.65 | $2,405 |
| 99213 Office E&M - Established | Office | 277 | 238 | $57.13 | $16K |
| 51797 Other Organ Systems | Office | 260 | 260 | $156.46 | $41K |
| 93980 Duplex Scan - Extremity Arteries | Office | 173 | 173 | $84.00 | $15K |
| 93975 Duplex Scan - Extremity Arteries | Office | 173 | 173 | $217.96 | $38K |
| 51784 Neurologic | Office | 128 | 64 | $48.33 | $6,186 |
| 99204 Office E&M - New | Office | 125 | 125 | $129.55 | $16K |
| 97750 Occupational Therapy | Office | 115 | 57 | $27.12 | $3,119 |
| 52214 Cystourethroscopy | Office | 115 | 114 | $584.79 | $67K |
| 90912 Behavioral Health Services | Office | 113 | 57 | $64.61 | $7,301 |
| 99214 Office E&M - Established | Office | 99 | 95 | $97.64 | $9,667 |
By year: 2022 $588K for 4,458 services; 2023 $598K for 3,934 services; 2024 $522K for 3,848 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81002 Clinical Chemistry | 331 | 291 | $3.41 | $1,129 |
| 36415 Venipuncture Blood Collection | 278 | 225 | $8.65 | $2,405 |
Medicare prescription drug claims, 2024
In 2024, the drug Shahin Derboghossians prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,908 prescriptions and refills. In total Shahin Derboghossians wrote 5,034 Medicare prescriptions that cost $525K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,908 | 2,131 | 278 | $9,442 |
| Gemtesa Vibegron | 667 | 687 | 131 | $323K |
| Dutasteride Generic | 479 | 513 | 67 | $4,073 |
| Doxazosin Mesylate Generic | 353 | 416 | 52 | $1,630 |
| Levofloxacin Generic | 311 | 311 | 249 | $579 |
| Tadalafil Generic | 302 | 788 | 86 | $100K |
| Finasteride Generic | 178 | 212 | 27 | $781 |
| Terazosin Hcl Generic | 152 | 158 | 19 | $628 |
| Myrbetriq Mirabegron | 103 | 107 | 17 | $49K |
| Fesoterodine Fumarate Er Fesoterodine Fumarate | 73 | 85 | Under 11 | $6,250 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 57 | 61 | Under 11 | $2,537 |
| Cialis Tadalafil | 44 | 47 | Under 11 | $13K |
| Dutasteride-Tamsulosin Dutasteride/Tamsulosin Hcl | 42 | 52 | Under 11 | $5,129 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 40 | 40 | 32 | $539 |
| Naproxen Generic | 27 | 27 | 19 | $49.06 |
Brand drugs: - claims; generic drugs: 4,205 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shahin Derboghossians $365 ($365 in general payments such as food, travel and fees) from 4 companies. The largest payer was Sumitomo Pharma America, Inc. with $262.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.